2019
|
|
Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1% read more...
|
|
2018
|
|
Akorn Receives FDA Approval for Diclofenac Sodium Topical Gel, 1% read more...
|
|
Akorn Receives FDA Approval for Clobetasol Propionate Lotion, 0.05% read more...
|
|
Akorn Receives FDA Approval for Bimatoprost Ophthalmic Solution, 0.03% read more...
|
|
2017
|
|
Akorn Receives FDA Approval for Mycophenolate Mofetil for Injection, USP read more...
|
|
2015
|
|
Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solution read more...
|
|
2014
|
|
Akorn Acquires Xopenex® (levalbuterol HCI) Inhalation Solution read more...
|
|
Akorn Acquires Hi-Tech Pharmacal. read more...
|
|
Akorn Acquires VersaPharm. read more...
|
|
2013-2014
|
|
Akorn Acquires Four Branded Ophthalmic Products: Zioptan®, CosoptPF/Cosopt®, AzaSite®, and Betimol®.
|
|
2012
|
|
Generic Vancocin® is approved and launched.
|
|
2011
|
|
Advanced Consumer Health is acquired to expand presence in a $1.2 billion over-the-counter eye care market. read more...
|
|
A Minority Stake in Aciex Therapeutics is acquired providing access to an innovative ophthalmic pipeline. read more...
|
|
Entered into agreement to acquire assets from Kilitch Drugs of India to expand manufacturing of sterile injectables and global reach. read more...
|
|
Nembutal®, a Schedule II controlled drug, Diuril® and Cogentin® are acquired from Lundbeck Pharma.
|
|
2010
|
|
The Akorn R&D Center in Skokie, IL is opened to provide leading edge capabilities for the development of new and generic pharmaceuticals.
|
|
2008
|
|
Corporate Headquarters are moved to Lake Forest, Illinois.
|
|
Warehousing is relocated to Gurnee, Illinois.
|
|
Akten® (lidocaine HCI ophthalmic gel) 3.5%, Akorn's first internally developed NDA indicated for topical ocular anesthesia is launched.
|
|
2007
|
|
Akorn, Inc. is listed on the NASDAQ exchange.
|
|
2004
|
|
Akorn Inc. and Strides Arcolab Ltd. enter into a joint venture as Akorn-Strides, LLC.
|
|
2002
|
|
Paremyd® (hydroxyamphetamine hydrobromide and tropicamide, ophthalmic solution), a convenient one-drop dilation agent is launched.
|
|
1998
|
|
Advanced Remedies Incorporated is acquired in Somerset, New Jersey, a division of Sidmak laboratories and manufacturer of sterile ophthalic ointments and solutions.
|
|
1997
|
|
Akorn Inc. is founded. Corporate headquarters and distribution offices are moved to Buffalo Grove, Illinois.
|
|
Indocyanine green, now IC-Green®, Akorn's first New Drug Application (NDA) ophthalmic drug for retina diagnostic imaging, is acquired from Becton Dickinson (BD).
|
|
1996
|
|
Taylor Pharmacal Company begins operating under the name of Akorn Manufacturing.
|
|
Pasadena Research Laboratories in Pasadena, California is acquired along with its injectable line of products.
|
|
1994
|
|
The Grand facility in Decatur is expanded to add ophthalmic filling operations.
|
|
1992
|
|
The Taylor family sells Taylor Pharmacal Company to Akorn Inc., a Louisiana based ophthalmic sales and distribution company, that owns ophthalmic products under the Akorn Ophthalmics label.
|
|
1977
|
|
The Wyckles facility in Decatur, Illinois is constructed to provide packaging and warehouse operation and to allow expansion of the filling and laboratory testing areas at the Grand facility.
|
|
1971
|
|
Akorn Ophthalmics is founded in Abita Springs, Louisiana
|
|
1953
|
|
The Grand facility in Decatur, Illinois is constructed to provide a filling and packaging location for the manufacture of pharmaceutical products.
|
|
1948
|
|
Taylor Pharmacal is founded by Guy Taylor and his two sons in Decatur Illinois.
|
|